ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
J Immunother Cancer. 2020 Apr;8(1):e000673. doi: 10.1136/jitc-2020-000673.
J Immunother Cancer. 2020.
PMID: 32317293
Free PMC article.